β-内酰胺/大环内酯联合治疗对社区获得性肺炎患者死亡率的影响:依据微生物病因与炎症状态
该研究为前瞻性观察性队列,纳入1996至2016年巴塞罗那医院收治的已知病原微生物的社区获得性肺炎患者。在1715例已知病原患者中,932例(54%)接受β-内酰胺联合大环内酯治疗。总体粗死亡率联合组5% vs 氟喹诺酮单用或联合β-内酰胺组8%(P=0.015),但经倾向评分和基线特征校正后,联合治疗仅对高炎症反应(C反应蛋白>15 mg/dL)且肺炎链球菌肺炎患者显示死亡率保护效应(校正OR 0.28,95%CI 0.09-0.93)。无高炎症反应且非肺炎链球菌肺炎或其他病原患者未见死亡率获益。
要点
- 在已知病原的CAP患者中,β-内酰胺联合大环内酯与氟喹诺酮单用或联合β-内酰胺相比,总体粗死亡率较低(5% vs 8%,P=0.015)。
- 校正后联合治疗的保护效应仅见于肺炎链球菌肺炎且C反应蛋白>15 mg/dL的患者(校正OR 0.28,95%CI 0.09-0.93)。
- 无高炎症反应且非肺炎链球菌肺炎患者,或其他病原所致CAP患者,联合治疗未见死亡率获益。
- 该研究为前瞻性观察性队列,已知病原患者共1715例,其中932例(54%)接受β-内酰胺联合大环内酯治疗。
适用人群与场景
- 1996至2016年巴塞罗那医院收治的社区获得性肺炎患者,仅纳入已知微生物病因者。
诊断标准与关键阈值
- 高炎症反应定义为C反应蛋白>15 mg/dL。
- 病原学确诊为肺炎链球菌肺炎。
研究设计与关键结果
- 研究类型:前瞻性观察性队列;已知病原CAP患者1715例,其中932例(54%)接受β-内酰胺联合大环内酯治疗。
- 总体粗死亡率:β-内酰胺联合大环内酯组5% vs 氟喹诺酮单用或联合β-内酰胺组8%(P=0.015)。
- 经倾向评分和基线特征校正后,β-内酰胺联合大环内酯仅对C反应蛋白>15 mg/dL且肺炎链球菌肺炎患者显示死亡率保护效应(校正OR 0.28,95%CI 0.09-0.93)。
- 无高炎症反应且非肺炎链球菌肺炎患者,或其他病原患者,未见死亡率获益。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于已知病原的CAP患者,β-内酰胺联合大环内酯的死亡率保护效应可能仅限于肺炎链球菌肺炎且C反应蛋白>15 mg/dL者(校正OR 0.28,95%CI 0.09-0.93)。
- 对于无高炎症反应且非肺炎链球菌肺炎患者,或其他病原所致CAP,联合治疗未见死亡率获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Antibiotic combinations that include macrolides have shown lower mortality rates than β-lactams in monotherapy or combined with fluoroquinolones in patients with community-acquired pneumonia (CAP). However, this effect has not been studied according to the levels of C-reactive protein in CAP with identified microbial cause. In patients with CAP and known microbial cause we aimed to evaluate 30-day mortality of a β-lactam plus macrolide (BL + M) compared with a fluoroquinolone alone or with a β-lactam (FQ ± BL).
METHODS: We analyzed a prospective observational cohort of patients with CAP admitted to the Hospital Clinic of Barcelona between 1996 and 2016. We included only patients with known microbial cause.
RESULTS: Of 1,715 patients (29%) with known etiology, a total of 932 patients (54%) received BL + M. Despite lower crude mortality in the BL + M group in the overall population (BL + M, 5% vs FQ ± BL, 8%; P = .015), after adjustment by a propensity score and baseline characteristics, the combination of BL + M had a protective effect on mortality only in patients with high inflammatory response (C-reactive protein, > 15 mg/dL) and pneumococcal CAP (adjusted OR, 0.28; 95% CI, 0.09-0.93). No benefits on mortality were observed for the population without high inflammatory response and pneumococcal CAP or with other etiologies.
CONCLUSIONS: The combination of a β-lactam with a macrolide was associated with decreased mortality in patients with pneumococcal CAP and in patients with high systemic inflammatory response. When both factors occurred together, BL + M was protective for mortality in the multivariate analysis.
参考来源
- Ceccato A, Cilloniz C, Martin-Loeches I, et al. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest. 2018. PMID: 30471269. doi:10.1016/j.chest.2018.11.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。